Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

November 5, 2024

Invitation to Presentation of Egetis’ Third Quarter 2024 Report

Read more

Regulatory

October 31, 2024

Egetis’ Nomination Committee for the 2025 Annual General Meeting

Read more

Regulatory

October 31, 2024

Change in the number of shares and votes in Egetis Therapeutics

Read more

Upcoming event

November 8, 2024

Interim Report Q3 2024 (7:00am CET)

Latest presentation

June 20, 2024

Replay of Triac Trial II topline results webcast

Latest Report

August 22, 2024

Interim report Q2 2024

Calendar and upcoming reports

November 8, 2024

Interim Report Q3 2024 (7:00am CET)

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]